CellReady is specifically designed to cut two years, and millions of dollars, off the path that cell and gene therapy (CGT) companies take to acquire the meaningful clinical inflection points that investors demand. CGT companies are funded by investors that expect to see their money generate meaningful clinical data before they make additional investments. But that rarely happens. Instead of spending the money on clinical data, CGT companies burn through 5%-10% of their investor's money each month while they struggle to create the essential building blocks of their CGT company, such as a quality management system, scalable manufacturing process, and a CMC section that is sure to clear FDA scrutiny. The CGT industry now faces a crisis. Investors no longer tolerate this time-consuming approach that leaves them empty handed. CellReady solves the problem by allowing CGT companies to hit the ground running with all of the essential building blocks they need to quickly gather meaningful clinical data. And CellReady is not driven solely by profit. CellReady will provide CGT companies with an optimized, scalable, and standardized G-Rex centric cell manufacturing process at virtually no charge, a nimble quality management system for free, ready-made sections of the CMC that will clear FDA review, and a vast array of expertise in all technical and business aspects of running a successful CGT company.